(Q35594009)

9 August 2017

1 reference

title

Evaluation of memantine for the treatment of Alzheimer's disease (English)

1 reference

9 August 2017

0 references

Steven H Ferris

1

0 references

language of work or name

English

0 references

publication date

1 December 2003

1 reference

Expert Opinion on Pharmacotherapy

9 August 2017

1 reference

9 August 2017

4

1 reference

9 August 2017

12

1 reference

9 August 2017

2305-2313

1 reference

Prospects for pharmacological intervention in Alzheimer disease

9 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Glutamate transmission and toxicity in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Excitatory Amino Acid Transmitters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

The role of excitotoxicity in neurodegenerative disease: implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

NMDA-receptor-dependent synaptic plasticity: multiple forms and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Investigations of neurotoxicity and neuroprotection within the nucleus basalis of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Non-cholinergic strategies for treating and preventing Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist--a review of preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Influence of urine pH and urinary flow on the renal excretion of memantine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Evaluation of memantine for neuroprotection in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

No interaction of memantine with acetylcholinesterase inhibitors approved for clinical use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Beyond intraocular pressure: neuroprotective strategies for future glaucoma therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Saving the nerve from glaucoma: memantine to caspaces

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.4.12.2305

10.1517/14656566.4.12.2305

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

14640929